Streetbeat News

KYMR

Kymera Therapeutics, Inc.

https://www.kymeratx.com

Industry

Biotechnology

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Analysts have provided mixed ratings for Kymera Therapeutics (NASDAQ:KYMR) over the past three months, with a majority being bullish. The average 12-month price target has increased slightly to $48.6. Financial metrics show positive revenue growth but challenges in ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

June 17, 2024 | 12:01 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics (NASDAQ:KYMR) and maintained a $46 price target.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 10:52 am

Kymera Therapeutics has shared new clinical data from its ongoing KT-333 Phase 1 trial. The data were presented at the European Hematology Association (EHA) Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2024 | 11:21 am

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics (NASDAQ:KYMR) and maintained a price target of $46.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 10:54 am

Kymera Therapeutics presented new clinical findings from its ongoing Phase 1 study of KT-253, an MDM2 degrader, at ASCO 2024. The study showed initial clinical proof of concept in patients with tumor types sensitive in preclinical models, including MCC and AML. KT-253 demonstrated target engagement and upregulation of p53 pathway biomarkers even at low doses and was generally well tolerated without hematologic adverse events. Additional data is expected in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 8:40 am

Kymera Therapeutics (NASDAQ:KYMR) received mixed ratings from 5 analysts over the past three months, with a majority being bullish. The average 12-month price target increased by 17.75% to $52.2. Analysts' actions include maintaining, raising, and lowering ratings, reflecting their response to recent developments. Kymera's financial performance shows impressive revenue growth and effective cost management, despite challenges in net margin and return on equity.

Portfolio Pulse from Benzinga Insights

May 24, 2024 | 12:01 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics (NASDAQ:KYMR) and maintained a price target of $46.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2024 | 11:04 am

Kymera Therapeutics plans to present new clinical data from its ongoing Phase 1 trial of MDM2 degrader KT-253 at the ASCO meeting. The company will also share its biomarker-based patient selection strategy and future development steps.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:24 pm

Kymera Therapeutics announced new preclinical data for KT-621, an oral STAT6 degrader, at the ATS Annual Meeting. KT-621 showed comparable or superior activity to dupilumab in preclinical asthma models. Phase 1 trials are expected to start in the second half of 2024, with data available in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 3:27 pm

Oppenheimer analyst Jeff Jones maintains an Outperform rating on Kymera Therapeutics (NASDAQ:KYMR) but lowers the price target from $53 to $52.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 1:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.